Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Hansoh Pharmaceutical Group Company Limited (3692.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
15.880-0.220 (-1.37%)
At close: 04:08PM HKT
Advertisement

Hansoh Pharmaceutical Group Company Limited

No.45 Huanghe Road
Economic & Technical Development Zone
Lianyungang 222069
China
86 21 3177 3517
https://www.hspharm.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees12,150

Key Executives

NameTitlePayExercisedYear Born
Ms. Huijuan ZhongChairlady, CEO & PresN/AN/A1961
Mr. Min HuVP & CFON/AN/A1977
Mr. Aifeng LyuExec. DirectorN/AN/A1977
Ms. Yuan SunExec. DirectorN/AN/A1987
Mr. Gongzheng WuSr. VPN/AN/A1971
Ms. Chunhua ZhongSr. VPN/AN/A1975
Mr. Chuanhe XuSr. VPN/AN/A1964
Mr. Rudi BaoSr. VPN/AN/A1964
Ms. Shengli ZhongJoint Company Sec. & Sr. VPN/AN/A1968
Ms. Yan Wing Li FCIS, FCS(PE)Joint Company Sec.N/AN/A1965
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.

Corporate Governance

Hansoh Pharmaceutical Group Company Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement